Amarillo Biosciences files IND for pulmonary fibrosis treatment

By Elaine Rigoli

Tampa, Fla., July 7 - Amarillo Biosciences, Inc. submitted an Investigational New Drug application to the Food and Drug Administration to begin a study of orally delivered interferon alpha in 60 patients with idiopathic pulmonary fibrosis (IPF).

These IPF patients will be enrolled in about six clinical sites in the United States.

The patients will be given interferon or a placebo for four weeks to assess the effect of treatment on chronic cough.

Amarillo Biosciences is a biotechnology company located in Amarillo, Texas.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.